Author

L. Richart

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 3 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Assay:DNA methylation· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:chromatin & epigenetic regulation· 1

Frequent Co-Authors

A. De Falco· 1 shared A. E. Lord· 1 shared A. Golebiewska· 1 shared A. Hamza· 1 shared A. Luscan· 1 shared A. Michaud· 1 shared A. Michelucci· 1 shared A. Mock· 1 shared

Activity by Year

2020-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 18 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. De Falco

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Persister cancer cells are characterized by H4K20me3 heterochromatin that defines a low inflammatory profile

V. Ramponi, L. Richart, M. Kovatcheva, C. Stephan-Otto Attolini, J. Capellades, A. E. Lord, O. Yanes, G. Ficz, M. Serrano

This study identifies H4K20me3 heterochromatin in persister cancer cells, which reduces their inflammatory profile and reveals vulnerabilities in one-carbon metabolism.

bioRxiv · Jan 26, 2024 · PreprintCancer Biology

EZH2 mutations in follicular lymphoma distort H3K27me3 profiles and alter transcriptional responses to PRC2 inhibition

P. Romero, L. Richart, S. Aflaki, M. Burton, A. Michaud, J. Masliah-Planchon, F. Kuhnoswki, C. Meaudre, A. Luscan, A. Hamza, P. Legoix, A. Vincent-Salomon, M. Wassef, D. Holoch, R. Margueron

This study shows that EZH2 mutations in follicular lymphoma alter H3K27 methylation and transcriptional responses to PRC2 inhibition, with clinical implications for patient stratification.

bioRxiv · Jan 2, 2023Cancer Biology

Primary and recurrent glioma patient-derived orthotopic xenografts (PDOX) represent relevant patient avatars for precision medicine

A. Golebiewska, A.-C. Hau, A. Oudin, D. Stieber, Y. A. Yabo, V. Baus, V. Barthelemy, E. Klein, S. Bougnaud, O. Keunen, M. Wantz, A. Michelucci, V. Neirinckx, A. Muller, T. Kaoma, , S. P. Niclou

This study shows that glioma PDOX models accurately represent patient tumors and can predict treatment responses in personalized medicine.

bioRxiv · Apr 24, 2020Cancer Biology